Ken Griffin Beyond Spring Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$1.74 - $2.47 $174 - $247	-100 Reduced 4.0%	2,400 $5,000
Q2 2024 Aug 14, 2024	BUY	$1.76 - $3.6 $1,232 - $2,520	700 Added 38.89%	2,500 $6,000
Q1 2024 May 15, 2024	BUY	$0.85 - $3.63 $255 - $1,089	300 Added 20.0%	1,800 $6,000
Q4 2023 Feb 14, 2024	BUY	$0.67 - $1.12 $268 - $448	400 Added 36.36%	1,500 $1,000
Q3 2023 Nov 14, 2023	SELL	$0.75 - $1.16 $75 - $115	-100 Reduced 8.33%	1,100 $0
Q2 2023 Aug 14, 2023	SELL	$0.89 - $1.39 $2,581 - $4,030	-2,900 Reduced 70.73%	1,200 $1,000
Q1 2023 May 15, 2023	BUY	$1.06 - $3.05 $2,226 - $6,405	2,100 Added 105.0%	4,100 $4,000
Q4 2022 Feb 14, 2023	BUY	$0.56 - $2.61 $1,120 - $5,220	2,000 New	2,000 $3,000

5.28M

200

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $68.1M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.